The European Patent Office (EPO) issued its final ruling last week rejecting a much-contested embryonic stem cell patent -- a decision that will likely be cheered by researchers and jeered by biotechs.
The patent covered technology developed by
James Thomson, a University of Wisconsin researcher, to culture primate embryonic stem cells derived from pre-implantation embryos. In last week's ruling, the EPO upheld a previous decision, made last...
Click to continue